Dicycloplatin
A platinum-based chemotherapy drug
| Dicycloplatin | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Dicycloplatin is a platinum-based chemotherapy drug used in the treatment of various types of cancer. It is a derivative of cisplatin, designed to improve upon the efficacy and reduce the side effects associated with traditional platinum-based therapies.
Chemical structure and properties
Dicycloplatin is a complex of platinum with a unique structure that includes a cyclobutane-1,1-dicarboxylate ligand. This structure is intended to enhance the drug's stability and solubility, making it more effective in targeting cancer cells.
Mechanism of action
Dicycloplatin works by binding to DNA in cancer cells, causing cross-linking that inhibits DNA replication and transcription. This ultimately leads to apoptosis, or programmed cell death, of the cancerous cells. The drug's mechanism is similar to that of other platinum-based drugs, but its unique structure may allow for different cellular uptake and distribution.
Clinical use
Dicycloplatin is used in the treatment of various cancers, including lung cancer, ovarian cancer, and colorectal cancer. It is often administered in combination with other chemotherapeutic agents to enhance its efficacy.
Side effects
As with other platinum-based drugs, dicycloplatin can cause a range of side effects. Common side effects include nausea, vomiting, nephrotoxicity, and myelosuppression. Efforts to reduce these side effects include careful dosing and supportive care measures.
Development and research
Research into dicycloplatin continues, with studies focusing on its effectiveness compared to other platinum-based drugs, its side effect profile, and its potential use in combination therapies. Ongoing clinical trials aim to better understand its role in cancer treatment.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD